JP7100056B2 - Ｌｉｆに対する抗体及びその使用 - Google Patents

Ｌｉｆに対する抗体及びその使用 Download PDF

Info

Publication number
JP7100056B2
JP7100056B2 JP2019554037A JP2019554037A JP7100056B2 JP 7100056 B2 JP7100056 B2 JP 7100056B2 JP 2019554037 A JP2019554037 A JP 2019554037A JP 2019554037 A JP2019554037 A JP 2019554037A JP 7100056 B2 JP7100056 B2 JP 7100056B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
certain embodiments
sequence described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019554037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512388A (ja
JP2020512388A5 (enExample
Inventor
スアレス，ジョアン セオアネ
フォルゲイラ，ジュディット アニード
フランソン，ヨハン
ジュリアン，ジャン－フィリペ
ラマン，スウェサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Priority claimed from PCT/IB2017/001677 external-priority patent/WO2018115960A1/en
Publication of JP2020512388A publication Critical patent/JP2020512388A/ja
Publication of JP2020512388A5 publication Critical patent/JP2020512388A5/ja
Priority to JP2022105552A priority Critical patent/JP7459173B2/ja
Application granted granted Critical
Publication of JP7100056B2 publication Critical patent/JP7100056B2/ja
Priority to JP2024044049A priority patent/JP2024075682A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019554037A 2016-12-19 2017-12-18 Ｌｉｆに対する抗体及びその使用 Active JP7100056B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022105552A JP7459173B2 (ja) 2016-12-19 2022-06-30 Ｌｉｆに対する抗体及びその使用
JP2024044049A JP2024075682A (ja) 2016-12-19 2024-03-19 Ｌｉｆに対する抗体及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16382617.5 2016-12-19
EP16382617 2016-12-19
US201762467017P 2017-03-03 2017-03-03
US62/467,017 2017-03-03
EP17382683 2017-10-13
EP17382683.5 2017-10-13
PCT/IB2017/001677 WO2018115960A1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105552A Division JP7459173B2 (ja) 2016-12-19 2022-06-30 Ｌｉｆに対する抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2020512388A JP2020512388A (ja) 2020-04-23
JP2020512388A5 JP2020512388A5 (enExample) 2021-05-13
JP7100056B2 true JP7100056B2 (ja) 2022-07-12

Family

ID=67138942

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019554037A Active JP7100056B2 (ja) 2016-12-19 2017-12-18 Ｌｉｆに対する抗体及びその使用
JP2022105552A Active JP7459173B2 (ja) 2016-12-19 2022-06-30 Ｌｉｆに対する抗体及びその使用
JP2024044049A Pending JP2024075682A (ja) 2016-12-19 2024-03-19 Ｌｉｆに対する抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022105552A Active JP7459173B2 (ja) 2016-12-19 2022-06-30 Ｌｉｆに対する抗体及びその使用
JP2024044049A Pending JP2024075682A (ja) 2016-12-19 2024-03-19 Ｌｉｆに対する抗体及びその使用

Country Status (24)

Country Link
US (2) US11390670B2 (enExample)
EP (2) EP4321219A3 (enExample)
JP (3) JP7100056B2 (enExample)
KR (3) KR102599557B1 (enExample)
CN (2) CN111868086B (enExample)
AU (1) AU2017381585B2 (enExample)
BR (1) BR112019012691A2 (enExample)
CA (1) CA3047528A1 (enExample)
CL (2) CL2019001717A1 (enExample)
DK (1) DK3555132T3 (enExample)
ES (1) ES2971126T3 (enExample)
FI (1) FI3555132T3 (enExample)
HR (1) HRP20240195T8 (enExample)
HU (1) HUE065241T2 (enExample)
IL (2) IL267450B (enExample)
LT (1) LT3555132T (enExample)
MX (2) MX2019007376A (enExample)
NZ (1) NZ755004A (enExample)
PL (1) PL3555132T3 (enExample)
RS (1) RS65187B1 (enExample)
SA (1) SA519402119B1 (enExample)
SI (1) SI3555132T1 (enExample)
SM (1) SMT202400065T1 (enExample)
ZA (1) ZA201904533B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3555132T (lt) * 2016-12-19 2024-02-26 Medimmune Limited Antikūnai prieš lif ir jų panaudojimas
SG11202009966SA (en) * 2018-04-12 2020-11-27 Medimmune Ltd Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
TWI841810B (zh) 2020-01-24 2024-05-11 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
CN117043189A (zh) 2020-12-31 2023-11-10 诺纳生物（苏州）有限公司 人lifr抗原结合蛋白及其制备方法和应用
TW202306993A (zh) * 2021-05-14 2023-02-16 美商建南德克公司 Ｔｒｅｍ２之促效劑

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539241A (ja) 2005-04-25 2008-11-13 ファイザー インコーポレイティッド ミオスタチンに対する抗体
JP2012522756A (ja) 2009-04-03 2012-09-27 フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2013523796A (ja) 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用
WO2016040657A1 (en) 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
WO2017089614A1 (en) 2015-11-27 2017-06-01 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Agents for the treatment of diseases associated with undesired cell proliferation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU4241693A (en) 1992-05-15 1993-12-13 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
EP1287832B1 (en) 1995-04-24 2005-12-21 Genentech, Inc. Use of leukemia inhibitory factor antagonist
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003085093A2 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2084185A4 (en) 2006-10-04 2010-11-17 Scripps Research Inst HUMAN ANTIBODIES THAT NEUTRALIZE HUMAN METAPNEUMOVIRUS
CN101440128A (zh) 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
IL275376B2 (en) 2013-03-11 2024-01-01 Genzyme Corp Hyperglycosylated binding polypeptides
US20140314741A1 (en) 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
US10633429B2 (en) 2013-08-20 2020-04-28 Japan Science And Technology Agency Human antibody κ type light chain complex-containing composition and method for producing same
US20150056195A1 (en) 2013-08-23 2015-02-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
US20160237158A1 (en) 2013-09-23 2016-08-18 Institut National De La Santé Et Da La Recherche Médicale (Inserm) Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis
JP6496719B2 (ja) 2013-10-09 2019-04-03 リサーチ ディベロップメント ファウンデーション モノクローナルｏｌｆｍｌ−３抗体及びその使用
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
WO2015106080A2 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
LT3555132T (lt) * 2016-12-19 2024-02-26 Medimmune Limited Antikūnai prieš lif ir jų panaudojimas
SG11202009966SA (en) * 2018-04-12 2020-11-27 Medimmune Ltd Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
KR20210024007A (ko) * 2018-06-18 2021-03-04 메디뮨 리미티드 암이 있는 개체에서 항-lif 항체 치료에 대한 반응을 개선하기 위한 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539241A (ja) 2005-04-25 2008-11-13 ファイザー インコーポレイティッド ミオスタチンに対する抗体
JP2012522756A (ja) 2009-04-03 2012-09-27 フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2013523796A (ja) 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用
WO2016040657A1 (en) 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
WO2017089614A1 (en) 2015-11-27 2017-06-01 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Agents for the treatment of diseases associated with undesired cell proliferation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K. Jim Kim et al.，Journal of Immunological Methods，1992年，Vol. 156，p. 9-17
Xiaoyan Li et al.，Oncotarget，2014年02月11日，Vol. 5, No. 3，p. 788-801

Also Published As

Publication number Publication date
IL267450A (en) 2019-08-29
SI3555132T1 (sl) 2024-04-30
EP4321219A2 (en) 2024-02-14
SMT202400065T1 (it) 2024-03-13
KR102716931B1 (ko) 2024-10-15
HRP20240195T1 (hr) 2024-04-26
JP2020512388A (ja) 2020-04-23
NZ755004A (en) 2025-08-29
JP2022130632A (ja) 2022-09-06
HRP20240195T8 (hr) 2024-05-24
CN111868086A (zh) 2020-10-30
CL2019001717A1 (es) 2020-02-28
DK3555132T3 (da) 2024-02-05
CL2021000950A1 (es) 2021-11-26
CA3047528A1 (en) 2018-06-28
EP4321219A3 (en) 2024-05-15
EP3555132A1 (en) 2019-10-23
KR20230125099A (ko) 2023-08-28
CN111868086B (zh) 2024-07-16
IL294088B2 (en) 2023-10-01
US11390670B2 (en) 2022-07-19
ZA201904533B (en) 2024-08-28
IL267450B (en) 2022-07-01
SA519402119B1 (ar) 2023-02-19
JP7459173B2 (ja) 2024-04-01
MX2024003178A (es) 2024-03-25
PL3555132T3 (pl) 2024-04-22
KR20240149987A (ko) 2024-10-15
HUE065241T2 (hu) 2024-05-28
IL294088B1 (en) 2023-06-01
BR112019012691A2 (pt) 2019-11-19
AU2017381585B2 (en) 2025-02-13
KR102784394B1 (ko) 2025-03-19
AU2017381585A1 (en) 2019-07-18
US20230042095A1 (en) 2023-02-09
ES2971126T3 (es) 2024-06-03
RS65187B1 (sr) 2024-03-29
IL294088A (en) 2022-08-01
KR102599557B1 (ko) 2023-11-07
JP2024075682A (ja) 2024-06-04
LT3555132T (lt) 2024-02-26
US20190352389A1 (en) 2019-11-21
MX2019007376A (es) 2020-02-07
EP3555132B1 (en) 2023-11-15
CN118652335A (zh) 2024-09-17
KR20190122652A (ko) 2019-10-30
FI3555132T3 (fi) 2024-02-08

Similar Documents

Publication Publication Date Title
JP7100056B2 (ja) Ｌｉｆに対する抗体及びその使用
US10206999B2 (en) Antibodies against LIF and uses thereof
AU2019251289B2 (en) Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer
JP2021523906A (ja) Ｌｉｆに対する抗体及びそれらの投与形態
JP7603772B2 (ja) 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
HK40107591A (en) Antibodies against lif and uses thereof
HK40042216A (en) Antibodies against lif and dosage forms thereof
BR122024020696A2 (pt) Anticorpo recombinante que se liga ao fator inibidor de leucemia e composição farmacêutica compreendendo o referido anticorpo
EA045781B1 (ru) Антитела к lif и их применения
HK40016422A (en) Antibodies against lif and uses thereof
HK40016422B (en) Antibodies against lif and uses thereof
HK40040276B (zh) 抗lif抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20201218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201218

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210125

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220630

R150 Certificate of patent or registration of utility model

Ref document number: 7100056

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250